What red flags should a small investor look for in a health-tech startup?

The same patterns that hid the Theranos fraud for fifteen years still show up in newer health-tech pitches, scaled down for a private or pre-IPO round. You don’t need a science PhD to catch most of them — you need a willingness to ask “show me” and walk away if the answer is no.

1. The board is more impressive than the data. A board of retired senators, surgeons general, or celebrity CEOs is a marketing asset, not a validation of the science. Elizabeth Holmes recruited Kissinger, Mattis, and Frist before any of them had seen a peer-reviewed result. If the advisors are louder than the published evidence, the deck is doing the work the data should be doing.

2. You can’t see the data, the model, or the raw output. Theranos hid behind NDAs and black boxes. Modern pitches do the same with “proprietary” AI models, “trade-secret” algorithms, and “regulatory constraints” that supposedly prevent disclosure. Ask: can you see the validation study, the sensitivity/specificity numbers, and a recent third-party replication? If no, that’s the answer.

3. The regulatory framing is “we don’t need FDA approval.” “Lab-developed test,” “wellness device,” “general wellness,” “informational only” — these are real FDA carve-outs, but they are also the loophole Theranos exploited. A health-tech company that proudly tells you they avoided FDA review is telling you they avoided the only independent check that catches fraud.

4. Retail rollout is faster than the science. Theranos had wellness centers in Walgreens before any peer-reviewed validation. If a startup is in CVS, Walgreens, or a chain clinic in year two with no published clinical data, the rollout is ahead of the evidence. That ordering — distribution before validation — is a recurring fraud pattern.

5. The founder story is the pitch. If the deck is 60% founder biography and 40% everything else, the science is thin. A real health-tech pitch leads with the patient outcome data, the regulatory pathway, and the cost model. The founder’s college-dropout or “I lost my grandmother” story is filler, not a substitute.

6. The same names keep turning up as advisors across unrelated health-tech companies. Some “advisors” collect retainers across 15 health AI startups and have never read any of their validation studies. Cross-check: search the advisor’s name against SEC filings or the FDA’s database of cleared devices. If they have never been involved in a successfully cleared product, their sign-off is social, not scientific.

The defensive move for a small investor is to treat any health-tech pitch with any of these six signals the way a credit card company treats a charge from a new country: don’t decline it on principle, but require extra verification. For the full Theranos story, see how Theranos fooled investors for over a decade, and for consumer-side fraud patterns to watch for, see how to protect your money from payment app scams.